Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences
Case report and literature review published in Journal of cardiovascular pharmacology (2016)
Abstract
Heparin-induced thrombocytopenia (HIT) is a life or limb-threatening thrombotic thrombocytopenia. HIT is traditionally treated with factor-IIa inhibitors such as bivalirudin, lepirudin, or argatroban. However, these agents usually require parenteral administration and are not generally available in all countries. Recently, several experiences with novel oral anticoagulants (NOACs) administration to treat HIT had been reported. NOACs generally offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of HIT with severe thrombotic complications successfully treated with rivaroxaban and discuss the current knowledge about the use of NOACs for the treatment of this potentially fatal thrombocytopenia.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Case report of heparin-induced thrombocytopenia presenting with deep venous thrombosis and pulmonary embolism, successfully treated with the oral anticoagulant rivaroxaban, with discussion of the emerging use of novel oral anticoagulants for HIT.
Context
This case report and review describes a patient with heparin-induced thrombocytopenia (HIT) presenting with severe thrombotic complications who was successfully treated with the oral factor Xa inhibitor rivaroxaban, and discusses current knowledge about novel oral anticoagulants for HIT. The review notes that HIT has traditionally been treated with parenteral direct thrombin inhibitors such as bivalirudin, lepirudin, or argatroban, situating hirudin-class agents within the HIT treatment landscape. Lepirudin is a recombinant hirudin derived from medicinal leech principles, and the article contextualizes such agents. However, the primary intervention was rivaroxaban, not a hirudin-based therapy, and the abstract does not provide patient demographics or specify the thrombotic complications; the article does not involve leech therapy or leech secretome preparations directly.
Citation
Reference (Vancouver style)
Samoš M, Bolek T, Ivanková J, Stančiaková L, Kovář F, Galajda P, et al. Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences. J Cardiovasc Pharmacol. 2016;68(5):391-394. doi:10.1097/FJC.0000000000000421. PMID: 27464495
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026